Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $UTHR
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/11/2024 | $310.00 → $321.00 | Overweight → Equal-Weight | Morgan Stanley |
2/12/2024 | $213.00 → $215.00 | Sell → Neutral | Goldman |
2/5/2024 | $330.00 | Outperform | Leerink Partners |
12/8/2023 | $309.00 | Overweight | Wells Fargo |
12/6/2022 | $320.00 | Buy | UBS |
12/5/2022 | $230.00 | Sell | Goldman |
10/11/2022 | $288.00 | Overweight | Morgan Stanley |
9/20/2022 | Underperform | BofA Securities |
United Therapeutics Named to '100 Best Companies to Work For' in 2025 by Fortune Media and Great Place to Work
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best Companies to Work For® in 2025. United Therapeutics ranked number 73 out of the 100 companies across the nation included in the list. "We are honored to be recognized by Fortune as one of the 100 Best Companies to Work For," said Michael Benkowitz, President & Chief Operating Officer of United Therapeutics. "This reflects a key management objective that United Therapeutics be a destination employer, where Unitherians can have their best career while fulfilling our mission to help very sick patients
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company's operations during a fireside chat session at the Leerink Partners Global Healthcare Conference 2025 in Miami Beach. The session will take place on Tuesday, March 11, 2025, from 10:00 a.m. to 10:30 a.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 da
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half
United Therapeutics downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded United Therapeutics from Overweight to Equal-Weight and set a new price target of $321.00 from $310.00 previously
United Therapeutics upgraded by Goldman with a new price target
Goldman upgraded United Therapeutics from Sell to Neutral and set a new price target of $215.00 from $213.00 previously
Leerink Partners initiated coverage on United Therapeutics with a new price target
Leerink Partners initiated coverage of United Therapeutics with a rating of Outperform and set a new price target of $330.00
Director Thompson Tommy G exercised 2,500 shares at a strike of $175.43 and sold $796,990 worth of shares (2,500 units at $318.80) (SEC Form 4)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
Director Patusky Christopher exercised 5,000 shares at a strike of $175.43 and sold $1,553,585 worth of shares (5,000 units at $310.72) (SEC Form 4)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
Chairperson & CEO Rothblatt Martine A gifted 229,947 shares and received a gift of 229,947 shares (SEC Form 4)
4 - UNITED THERAPEUTICS Corp (0001082554) (Issuer)
United Therapeutics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
SEC Form 10-K filed by United Therapeutics Corporation
10-K - UNITED THERAPEUTICS Corp (0001082554) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by United Therapeutics Corporation
SCHEDULE 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
IM Therapeutics Announces Appointment of Jonathan Rigby to Board of Directors
WOBURN, Mass.--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, Inc. (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, announced today that Jonathan Rigby has joined its Board of Directors. Mr. Rigby brings extensive company building and pipeline development experience in autoimmune and other diseases. IM Therapeutics is developing small molecule oral genetic medicines targeting specific human leukocyte antigen (HLA) variants known to play a strong role in autoimmune diseases. The Company’s lead drug candidate, IMT-002, is in Phase 1b clinical trials in type 1 diabetes (T1D). Patients in the study were preselected for HLA-DQ8, the
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. "I want to congratulate every Unitherian for their relentless dedication, which has allowed us to deliver a third consecutive year of record revenue," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of that, our three-year cascade of clinical and regulatory events is under way: both TETON studies in idiopathic pulmonary fibrosis are enrolled, facilitating data starting the second half
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2024 financial results before the market opens on Wednesday, February 26, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast Wednesday, February 26, 2025, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at https://ir.unither.com/events-and-presentations. A rebroadcast of the webcast will be available for one year and can be accessed at the same location. United Therapeutics: Enabling Inspiration At United Therapeutics,
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the close to 1,300 Unitherians who have contributed to yet another record revenue quarter and reaching a $3 billion annual revenue run rate in the third quarter," said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. "On top of our stellar revenue performance, 2025 marks the start of a multi-year cascade of clinical data reads and r
Amendment: SEC Form SC 13G/A filed by United Therapeutics Corporation
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SEC Form SC 13G filed by United Therapeutics Corporation
SC 13G - UNITED THERAPEUTICS Corp (0001082554) (Subject)
SEC Form SC 13G/A filed by United Therapeutics Corporation (Amendment)
SC 13G/A - UNITED THERAPEUTICS Corp (0001082554) (Subject)